Anavex Life Sciences Corp (AVXL)

[WolfWayne]

Question to the board: when a company requests and extension to a portion of a trial, what criteria does the FDA use when approving or denying an extension request?

Given the patient-requested P2A PartB extension, and the fact it seems the FDA has granted approval, I'd like to know if this is business as usual or if this is a tell-tale sign the data might be valued by the FDA.